Zobrazeno 241 - 250
of 345
pro vyhledávání: '"Andrew L. Feldman"'
Publikováno v:
The American journal of surgical pathology. 36(9)
CD3 expression by immunohistochemistry was historically considered restricted to T-lineage or NK-lineage neoplasms but recently has been reported in rare cases of mature B-cell neoplasms, frequently in association with Epstein-Barr virus. Here, we de
Publikováno v:
Journal of cutaneous pathology. 40(2)
Lymphomatoid papulosis (LyP) and cutaneous anaplastic large cell lymphoma (ALCL) belong to the spectrum of cutaneous CD30+ lymphoproliferative disorders, an indolent form of T-cell lymphoproliferative disease. We reviewed 21 cases of CD30+ lymphoprol
Autor:
Dragana Milosevic, Irina V. Kovtun, N. Sertac Kip, Yan W. Asmann, George Vasmatzis, Sarah H. Johnson, Mark E. Law, Nazan Özsan, Andrew L. Feldman, Ahmet Dogan, David I. Smith, Rhett P. Ketterling, Bruce W. Eckloff, Ryan A. Knudson, David S. Viswanatha, Lori Frederick, Marshall E. Kadin, Stephen M. Ansell, E. Aubrey Thompson, Stefan K.G. Grebe, Julie C. Porcher, Esteban Braggio, Rafael Fonseca
WOS: 000309044200020
PubMed ID: 22855598
Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only similar to 35%. Improvement in outcomes has been stymied by poor und
PubMed ID: 22855598
Peripheral T-cell lymphomas (PTCLs) are aggressive malignancies of mature T lymphocytes with 5-year overall survival rates of only similar to 35%. Improvement in outcomes has been stymied by poor und
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83ee0401dbd2b9027f98f35e0af8bd17
https://hdl.handle.net/11454/46600
https://hdl.handle.net/11454/46600
Autor:
Lorenz Trümper, German Ott, Andrew L. Feldman, Margaretha G.M. Roemer, Donna Neuberg, Marita Ziepert, Markus Löffler, Heike Horn, Michael Pfreundschuh, Andrew Dunford, Jaegil Kim, Todd R. Golub, Stefano Monti, Anne J. Novak, Bjoern Chapuy, Gerald Wulf, Amy Li, Andreas Rosenwald, Gad Getz, Michael S. Lawrence, Mara Rosenburg, Reiner Siebert, Atanas Kamburov, Chip Stewart, Brian K. Link, Julian M. Hess, Amaro Taylor-Weiner, Scott J. Rodig, Margaret A. Shipp, Robert A. Redd, James R. Cerhan, Thomas M Haberman
Publikováno v:
Blood. 126:3922-3922
Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous disease characterized by multiple low-frequency alterations including somatic mutations, copy number alterations (CNAs) and chromosomal rearrangements. We sought to identify previou
Autor:
Yan W. Asmann, James R. Cerhan, Stephen M. Ansell, Brian K. Link, Susan L. Slager, Matthew J. Maurer, Andrew L. Feldman, Vivekananda Sarangi, Chen Wang, Thomas M. Habermann, Anne J. Novak, Grzegorz S. Nowakowski
Publikováno v:
Blood. 126:131-131
Tumors arise and evolve by iterative steps of mutation, subclonal selection, and clonal expansion due to growth advantage of the fittest subclones and external mutation induction and selection pressure from radiation and drug therapies. Various studi
Publikováno v:
Blood. 126:2673-2673
Gene expression profiling has identified two major subclasses of diffuse large B-cell lymphoma. Cases resembling germinal center B-cells (GCB-DLBCL) generally occur in younger patients, have a distinct molecular pathophysiology, and have improved out
Autor:
Bruce W. Eckloff, Julie M. Cunningham, Surendra Dasari, Yanhong Wu, Andrew L. Feldman, Julie C. Porcher, Brian K. Link, Jean-Pierre A. Kocher, Michael T. Zimmermann, James R. Cerhan, Rebecca L. Boddicker, Yu Zeng, Stephen M. Ansell
Publikováno v:
Blood. 126:2681-2681
Background: Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of relatively uncommon and generally aggressive non-Hodgkin lymphomas. Recent studies have begun to reveal their mutational landscape, such as the recurrent mutations affe
Autor:
Anthony Pham, Dragan Jevremovic, Matthew J. Maurer, Stephen M. Broski, Kay M. Ristow, Gregory A. Wiseman, Andrew L. Feldman, Thomas M. Habermann, Thomas E. Witzig
Publikováno v:
Blood. 126:3947-3947
INTRODUCTION: Adult mature T- and NK-cell neoplasms are a heterogeneous group of aggressive lymphomas comprising approximately 10% to 20% of all non-Hodgkin lymphomas (NHL) with an estimated 5-year overall survival of 40%. Staging and treatment strat
Autor:
Karin E. Smedby, Brian K. Link, Matthew J. Maurer, Thomas Relander, Fredrik Ellin, Mats Jerkeman, Sergei Syrbu, Carrie A. Thompson, William R. Macon, Thomas E. Witzig, Stephen M. Ansell, Susan L. Slager, Andrew L. Feldman, James R. Cerhan, Thomas M. Habermann
Publikováno v:
Blood. 126:1501-1501
Background: Peripheral T-Cell lymphomas (PTCLs) constitute approximately 10% of lymphoid malignancies and consist of several distinct entities based on pathologic and clinical characteristics. With the exception of a few subtypes (e.g., ALK-positive
Autor:
Richard M. Weinshilboum, Liewei Wang, Matthew K. Breitenstein, Carrie A. Thompson, Thomas E. Witzig, Umar Farooq, Curtis Olswold, James R. Cerhan, Anne J. Novak, Andrew L. Feldman, Thomas M. Habermann, Susan L. Slager, Grzegorz S. Nowakowski, Brian K. Link, Matthew J. Maurer, Stephen M. Ansell
Publikováno v:
Molecular Cancer Therapeutics. 14:B143-B143
Background: Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy is standard of care for patients with newly diagnosed DLBCL. A majority of patients respond to R-CHOP, however ∼9% will have primary refractory disea